FUZEON Drug Patent Profile

Which patents cover Fuzeon, and what generic alternatives are available?

Fuzeon is a drug marketed by Roche and is included in one NDA.

The generic ingredient in FUZEON is enfuvirtide. Additional details are available on the enfuvirtide profile page.

Summary for FUZEON

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	28
Clinical Trials:	24
Patent Applications:	4,963
Drug Prices:	Drug price information for FUZEON
What excipients (inactive ingredients) are in FUZEON?	FUZEON excipients list
DailyMed Link:	FUZEON at DailyMed

See drug prices for FUZEON

Recent Clinical Trials for FUZEON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sidney Kimmel Comprehensive Cancer Center	Early Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)	Early Phase 1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Early Phase 1

See all FUZEON clinical trials

US Patents and Regulatory Information for FUZEON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	FUZEON	enfuvirtide	INJECTABLE;SUBCUTANEOUS	021481-001	Mar 13, 2003		DISCN	Yes	No

Expired US Patents for FUZEON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche	FUZEON	enfuvirtide	INJECTABLE;SUBCUTANEOUS	021481-001	Mar 13, 2003	5,464,933
Roche	FUZEON	enfuvirtide	INJECTABLE;SUBCUTANEOUS	021481-001	Mar 13, 2003	6,133,418
Roche	FUZEON	enfuvirtide	INJECTABLE;SUBCUTANEOUS	021481-001	Mar 13, 2003	6,475,491

EU/EMA Drug Approvals for FUZEON

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Roche Registration GmbH	Fuzeon	enfuvirtide	EMEA/H/C/000514Fuzeon is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected patients who have received treatment with and failed on regimens containing at least one medicinal product from each of the following antiretroviral classes: protease inhibitors, non-nucleoside reverse-transcriptase inhibitors and nucleoside reverse-transcriptase inhibitors, or who have intolerance to previous antiretroviral regimens.In deciding on a new regimen for patients who have failed an antiretroviral regimen, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different medicinal products. Where available, resistance testing may be appropriate.	Authorised	no	no	no	2003-05-27

International Patents for FUZEON

See the table below for patents covering FUZEON around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	774971
European Patent Office	0831873
Brazil	9609152
Mexico	9709682	EL TRATAMIENTO DE INFECCIONES VIH Y OTRAS INFECCIONES VIRALES USANDO UNA TERAPIA COMBINADA. (THE TREATMENT OF HIV AND OTHER VIRAL INFECTIONS USING COMBINATORY THERAPY.)

Supplementary Protection Certificates for FUZEON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0774971	C300192	Netherlands		PRODUCT NAME: ENFUVIRTIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER; NAT. REGISTRATION NO/DATE: EU/1/03/252/001EU/1/03/252/002EU/1/03/252/003 2003270527; FIRST REGISTRATION: CH/56282 20030430
0774971	SPC/GB05/026	United Kingdom		PRODUCT NAME: ENFUVIRTIDE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER; REGISTERED: CH CH 56,282 20030430; UK EU/1/03/252/001 20030527; UK EU/1/03/252/002 20030527; UK EU/1/03/252/003 20030527
0774971	CA 2005 00042	Denmark
0774971	SPC014/2005	Ireland		SPC014/2005: 20090409, EXPIRES: 20180924

Market Dynamics and Financial Trajectory for FUZEON (Enfuvirtide)

Last updated: February 3, 2026

Executive Summary

FUZEON (generic name: Enfuvirtide) is a fusion inhibitor antiviral therapy developed by Hoffmann-La Roche and subsequently marketed by Genentech, a member of the Roche Group. Approved by the U.S. Food and Drug Administration (FDA) in 2003, FUZEON targets HIV-1 by preventing viral entry into host cells. Despite initial enthusiasm, its market share has faced challenges due to pharmacological complexity, administration route, and competition from newer antiretroviral agents. This report delineates the current market landscape, sales trajectories, competitive positioning, regulatory standards, and future outlook for FUZEON.

---

1. Overview of FUZEON: Product Profile

Attribute	Details
Generic Name	Enfuvirtide
Brand Name	FUZEON
Therapeutic Area	HIV-1 Antiretroviral Therapy
Approval Year	2003 (FDA)
Mechanism of Action	Fusion inhibitor; prevents HIV-1 fusion with CD4+ T cells
Administration Route	Subcutaneous injection (typically BID)
Dosage & Packaging	90 mg per injection; 24-vial or pre-filled syringes
Target Demographic	Adults and adolescents (≥6 years) with treatment-experienced HIV infections

---

2. Market Dynamics

2.1. Market Penetration & Adoption

Since its initial FDA approval, FUZEON has maintained a niche position within antiretroviral therapy (ART). As of 2022, it is predominantly prescribed for patients with multi-drug resistant HIV strains or those intolerant to other agents. Key factors influencing its market penetration include:

• Administration Complexity: Requires twice-daily subcutaneous injections, affecting patient compliance.
• Side Effect Profile: Local injection site reactions (up to 98%) and occasional systemic adverse events limit broader use.
• Pricing & Reimbursement: High per-treatment costs (~$20,000/year) impact accessibility and insurance coverage considerations.

2.2. Competitive Landscape

The emergence of integrase strand transfer inhibitors (INSTIs) and other potent ART classes has reshaped the HIV treatment market.

Competitors (Key Drugs)	Class	Market Share (2022)	Notable Features
Dolutegravir (Tivicay, DTG)	INSTI	60%	Once daily dosing, fewer side effects, high potency
Raltegravir (Isentress)	INSTI	8%	Effective for treatment-experienced patients
Bictegravir (Biktarvy)	INSTI + NRTI combination	12%	Single-tablet regimen, high barrier to resistance
Maraviroc (Selzentry)	CCR5 antagonist	3%	Used for CCR5-tropic HIV

FUZEON's market share continues at roughly 2-3%, primarily restricted to salvage therapy cases.

2.3. Regulatory and Policy Influences

Regulatory guidelines and insurance policies influence FUZEON's market. The US Department of Health and Human Services' guidelines favor more convenient, effective, and tolerable regimens, further constraining FUZEON’s broader application.

---

3. Financial Trajectory

3.1. Sales Performance Overview

Year	Estimated Global Sales (USD millions)	Comments
2003	$354	Launch year, rapid initial adoption
2005	$400	Market stabilization, high-cost niche use
2010	$280	Declined due to competition and dosing complexity
2015	$150	Further decline, specialty-only use
2020	$110	Sustained but shrinking market
2022	~$105	Approximate, estimated from market reports

Note: Precise sales data are proprietary; estimates derive from industry analyses (e.g., EvaluatePharma, IQVIA).

3.2. Revenue Drivers & Challenges

Driver	Impact	Challenges
Drug efficacy in resistant cases	Maintains niche demand	Limited to select patient populations
Innovative competitors	Eroding market share	Better tolerated, simpler regimens reduce FUZEON appeal
Reimbursement policies	Influences prescribing patterns	High costs limit outpatient prescribing
New drug development	Threatens long-term viability	Emerging therapies may obviate need for fusion inhibitors

---

4. Market Forecast & Outlook

4.1. Short-to-Medium Term (2023-2028)

• Growth potential: Minimal; estimated annual growth rate of ~1-2% due to its niche status.
• Market contraction: Expected as newer oral agents improve tolerability and simplify regimens.
• Regulatory approvals: No major new indications expected; existing approvals maintained.
• Patent & exclusivity: No current patent exclusivity barriers; generic versions possible post-2023.

4.2. Long-Term Outlook (2028+)

• Market decline: Predicted to phase out as HIV management shifts toward integrase-based regimens.
• Remnant use: Limited to very specific, resistant cases.
• Potential for reformulation: Any new delivery methods (e.g., longer-acting injectables) could revitalize interest.

---

5. Strategic Insights

Strategy	Rationale
Development of Longer-Acting Formulations	Improve compliance, reduce injection frequency
Targeted Marketing to Specialty Clinics	Focus on salvage therapy and treatment-resistant cases
Combination Regimens	Integration with other agents for combination therapies
Licensing & Partnerships	Expand access in emerging markets or through biosimilar options

---

6. Comparative Analysis With Similar Drugs

Aspect	FUZEON (Enfuvirtide)	Selzentry (Maraviroc)	Ibalizumab (Trogarzo)
Mechanism	Fusion inhibitor	CCR5 antagonist	Post-attachment HIV inhibitor
Approval Year	2003	2007	2018
Route of Administration	Subcutaneous injection	Oral	IV infusion
Dosing Frequency	BID	Once daily	Weekly or biweekly
Market Share (2022)	2-3%	3%	Very limited
Main Use Case	Salvage, resistant HIV cases	CCR5-tropic HIV	Multiresistant HIV

---

7. Regulatory & Policy Environment

Agency / Policy	Influence on Market Dynamics
FDA	Approves new formulations, monitors safety
EMA	Similar role in Europe
CDC & WHO Guidelines	Favor simpler, once-daily regimens, de-emphasize fusion inhibitors
Reimbursement Policies	Favor cost-effective, convenient therapies

---

8. FAQs

Q1: Why has FUZEON maintained only a niche market since its approval?
Because of its administration complexity, side effect profile, and competition from newer, easier-to-use oral therapies.

Q2: Are there efforts to improve FUZEON’s delivery or efficacy?
Yes, ongoing research aims at longer-acting formulations, subcutaneous depots, or combination delivery systems to improve adherence.

Q3: What patient populations are most likely to benefit from FUZEON today?
Patients with multidrug-resistant HIV strains who have failed multiple other regimens where alternatives are limited.

Q4: How does the cost of FUZEON impact its market dynamics?
High costs limit accessibility and insurance coverage, reinforcing its 'salvage therapy' status.

Q5: What is the future outlook for FUZEON in HIV management?
Expect continued decline in market share as integrase-based therapies become dominant; potential niche use persists with formulations improving compliance.

---

9. Key Takeaways

• FUZEON’s sales peaked early post-approval but have steadily declined due to pharmacological and strategic factors.
• It remains critical for treatment-resistant HIV cases but faces significant headwinds from oral, once-daily regimens with better tolerability.
• The drug’s market trajectory is expected to diminish further over the next 5-10 years, aligning with advances in ART.
• Opportunities exist in developing long-acting delivery systems or combining FUZEON with other agents to extend its utility.
• Strategic focus on niche markets and resistant cases will sustain FUZEON’s relevance, albeit marginally, in the evolving HIV therapy landscape.

---

References

[1] U.S. Food and Drug Administration (FDA). Drug Approval Packages, 2003.
[2] EvaluatePharma, "Global HIV Market 2022," 2022.
[3] IQVIA, "Pharmaceutical Market Insights," 2022.
[4] CDC HIV Treatment Guidelines, 2022.
[5] European Medicines Agency (EMA), "Assessment Reports," 2003-2022.